A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

555

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Remibrutinib Dose A
DRUG: Remibrutinib Dose B
DRUG: Placebo 1
DRUG: Placebo 2

Sponsor

Novartis Pharmaceuticals